4.7 Article

Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis

Journal

Publisher

BMC
DOI: 10.1186/s13046-022-02242-3

Keywords

PCMT1; Metastasis; Extracellular matrix; CRISPR; Cas9; Integrin-FAK-Src; Anoikis

Categories

Funding

  1. Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support [20172003]
  2. Natural Science Foundation of Shanghai [20ZR1433700]
  3. National Natural Science Foundation of China [81872345]
  4. Innovative Research Team of High-Level Local Universities in Shanghai [SSMU-ZDCX20180800]

Ask authors/readers for more resources

This study identified PCMT1 as a critical driver of resistance to detachment-induced apoptosis in ovarian cancer cells. PCMT1 enhanced cell migration, adhesion and spheroid formation through interaction with the ECM protein LAMB3. Treatment with an antibody against extracellular PCMT1 reduced cancer cell invasion and adhesion. PCMT1 was highly expressed in late-stage metastatic tumors, suggesting its potential as a therapeutic target in metastatic ovarian cancer.
Background The development of lethal cancer metastasis depends on the dynamic interactions between cancer cells and the tumor microenvironment, both of which are embedded in the extracellular matrix (ECM). The acquisition of resistance to detachment-induced apoptosis, also known as anoikis, is a critical step in the metastatic cascade. Thus, a more in-depth and systematic analysis is needed to identify the key drivers of anoikis resistance. Methods Genome-wide CRISPR/Cas9 knockout screen was used to identify critical drivers of anoikis resistance using SKOV3 cell line and found protein-L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1) as a candidate. Quantitative real-time PCR (qRT-PCR) and immune-histochemistry (IHC) were used to measure differentially expressed PCMT1 in primary tissues and metastatic cancer tissues. PCMT1 knockdown/knockout and overexpression were performed to investigate the functional role of PCMT1 in vitro and in vivo. The expression and regulation of PCMT1 and integrin-FAK-Src pathway were evaluated using immunoprecipitation followed by mass spectrometry (IP-MS), western blot analysis and live cell imaging. Results We found that PCMT1 enhanced cell migration, adhesion, and spheroid formation in vitro. Interestingly, PCMT1 was released from ovarian cancer cells, and interacted with the ECM protein LAMB3, which binds to integrin and activates FAK-Src signaling to promote cancer progression. Strikingly, treatment with an antibody against extracellular PCMT1 effectively reduced ovarian cancer cell invasion and adhesion. Our in vivo results indicated that overexpression of PCMT1 led to increased ascites formation and distant metastasis, whereas knockout of PCMT1 had the opposite effect. Importantly, PCMT1 was highly expressed in late-stage metastatic tumors compared to early-stage primary tumors. Conclusions Through systematically identifying the drivers of anoikis resistance, we uncovered the contribution of PCMT1 to focal adhesion (FA) dynamics as well as cancer metastasis. Our study suggested that PCMT1 has the potential to be a therapeutic target in metastatic ovarian cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available